ACUD-1 is under clinical development by Accuitis and currently in Phase II for Rosacea. According to GlobalData, Phase II drugs for Rosacea have a 38% phase transition success rate (PTSR) indication ...

Deucravacitinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Rosacea. According to GlobalData, Phase II drugs for Rosacea have a 38% phase transition success ...

Researchers say a compound called SYM2081 inhibits inflammation-driving mast cells in mice and human skin samples paving the ...

Some people develop irritated eyes or thickening skin. 36,37 Although there is no cure for rosacea, proper treatment can help control the condition. While people of all ages and races can develop ...

Vee Mistry, CEO of SKINBYVEE shares what it takes to form strategic partnerships, put customers first, and pro-aging.

As the science of skin care continues to expand, some of those advances have landed directly in consumers’ hands. Is that a ...

In recent years, skin tightening treatment has become increasingly popular as more and more people are looking for ...

Medically reviewed by Susan Bard, MD Dermaplaning is a minimally invasive exfoliating treatment that uses a small blade to ...

I'm a big K-beauty fan so, naturally, I love a hydrating essence. Because Palacios loves this brand, I decided to try the one ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Beauty chasers are suddenly shelling out hundreds of dollars for something called “semipermanent blush,” a new kind of ...

The stock’s fifty day moving average is $1.26 and its 200-day moving average is $1.76. The stock has a market cap of $2.77 million, a price-to-earnings ratio of -0.08 and a beta of 0.79. An ...